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Abstract. The criteria for distinction between independent 
primary tumors and metastasis from one site to the other in 
synchronous endometrioid endometrial and ovarian carcinoma 
(SEO) has been a matter of dispute for a long time. In our 
study we performed a comprehensive clinico-pathological and 
molecular analysis of 22 cases of SEO. Based on conventional 
clinico‑pathological criteria the cases were classified as indepen-
dent primary tumors (10 cases) and metastasis from one location 
to the other (12 cases). All tumors were analyzed by NGS with a 
panel of 73 genes (219 kbp). Clonal origin was confirmed in all 
cases by at least one shared mutation in PTEN, AKT1, PIK3CA, 
KRAS, TP53 and ARID1A. Two patients carried germline 
pathogenic mutation in cancer-predisposing genes BRCA1 or 
BARD1. Microsatellite instable phenotype was detected in 5/22 
(22.7%) SEO, but in one case only in the endometrial tumor. In 
conclusion, our results showed that all 22 SEOs were clonally 
related, irrespectively of their clinico-pathological features. 
Even low grade and low stage tumors classified as independent 
primaries, according to the conventional morphological criteria, 
have a clonal origin. From the practical point of view, only the 
conventional morphological criteria should be used for the clas-
sification (staging) of these tumors. However, molecular profiling 
of these tumors may have prognostic and predictive meaning.
Introduction
Synchronous endometrial and ovarian carcinomas occur in 
approximately 5% of endometrial carcinomas and 10-20% of 
ovarian carcinomas, respectively (1,2). The distinction between 
independent primary tumors and metastasis from one site to the 
other (endometrium to the ovary or ovary to the endometrium) 
can be complicated but it is clinically significant. Historically, 
the criteria for this distinction evolved and were based mostly 
on morphological features (3,4). However, a great benefit has 
been expected from ancillary methods (especially molecular 
analyses) which are now becoming, together with method-
ological development, more complex and also more available. 
Surprisingly, the results of recent molecular studies have shown 
that most SEOs share clonal origin irrespectively of their clin-
ico-pathological features (5-7). The benefit of molecular analysis 
regarding differential diagnosis between independent primary 
tumors and metastatic disease is, from this point of view, disput-
able. Nevertheless, in one recent study the authors suggested 
that molecular profiling might be beneficial in this setting (8). 
However, this suggestion was based on molecular profiling of 
one SEO only. In our study we focused on a comprehensive 
clinico-pathological and molecular study of 22 cases of SEO.
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Materials and methods
Patients and materials. Archive files of the: i) Institute of 
Pathology, First Faculty of Medicine, Charles University 
and General University Hospital in Prague, Czech Republic; 
ii) The Fingerland Department of Pathology, Charles 
University Faculty of Medicine and University Hospital 
Hradec Králové, Czech Republic; and iii) Department of 
Pathology, University of Debrecen, Hungary, were searched for 
synchronous cases of endometrioid endometrial and ovarian 
carcinomas. Twenty-two SEOs were found with corresponding 
formalin‑fixed paraffin‑embedded tissue (FFPE) blocks from 
both endometrial and ovarian tumors. One patient with SEO 
also had synchronous CCCO arising in the second ovary. 
Another patient had endometrioid carcinoma of the left ovary 
and after 49 months she developed SEO (of the endometrium 
and right ovary). Histological type, staging and grading of EEC 
and EOC were assessed for each tumor separately according 
to the standard criteria (9). A review of the hematoxylin and 
eosin stained slides was performed in all cases, and the area 
of tumor tissue for macrodissection was marked (percentage 
of tumor cells in selected area ranges between 30 and 90%).
DNA from FFPE blocks was isolated using standard 
procedures implementing QIAamp DNA Tissue kit (Qiagen, 
Hilden, Germany) or cobas® DNA Sample Preparation kit 
(Roche, Basel, Switzerland), respectively.
Sequencing analysis. The whole project and all auxiliary 
files are designed for genome build GRCh37 (hg 19) coordi-
nates. Samples for sequence capture NGS (massive parallel 
sequencing) were prepared using the KAPA HyperPlus kit. 
Target sequences were enriched using commercial hybridiza-
tion probes (Nimblegen, Roche) designed for human DNA 
regions of our interest (73 genes or gene parts; 219 kbp). The 
panel included the following genes: AKT1, AKT3, ARID1A, 
ARID2, ATM, BAP1, BARD1, BIRC5 (promoter), BRAF 
(exon 11,15), BRCA1, BRCA2, BRIP1, CCND2, CCND3, 
CDH1, CDK4, CDKN2A, CYP19A1, ERBB2, ERCC3, ESR1, 
ESR2, F11R, FOXL2, GNA11, GNAQ, HNF1B, HRAS, IDH1, 
JAM2, JAM3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MAPK1, 
MAPK3, MDM2, MET, MITF, MLH1, MLH3, MSH2, MSH6, 
MYC, NBN, NRAS, PALB2, PARD3, PDGFRA (exon 12,14,18), 
PIK3CA, POLE, POT1, PPM1D, PPP6C, PTEN, RAD51C, 
RAD51D, RB1, SF3B1, SMARCA4, SMARCB1, SNAI1, SNAI2, 
SNAI3, TERT (promoter), TJP1, TP53, TWIST1, TWIST2, 
ZEB1, ZEB2. The library was pair-end sequenced by MiSeq 
instrument (Illumina, Inc., San Diego, CA, USA).
Selected germline variants and selected variants with a 
frequency higher than 10% were confirmed by direct Sanger 
sequencing using BigDye v3.1 and ABI3500 analyzer (Thermo 
Fisher Scientific, Inc., Waltham, MA, USA).
The processing of raw sequencing data was performed 
to analyze the spectrum of genetic variants, such as single 
nucleotide variants and short insertions or deletions using 
NextGENe software (SoftGenetics LLC, State College, 
PA, USA) according to the standardized biostatistical 
methods for NGS data. Primary raw data were trimmed 
and demultiplexed by MiSeq system during post-sequencing 
process. Output in .fastq format was complexly analyzed by 
NextGENe software (SoftGenetics LLC). The PCR duplicate 
reads were removed by Sequence Operation Tool (default 
settings), then .fastq files were converted by using Format 
Conversion Tool to .fasta format. During conversion, reads 
with low quality were removed (Settings: Median score 
threshold ≥25; Max # of uncalled bases ≤2; Called base 
number of each read ≥40; Trim or reject read when ≥3 base(s) 
with score ≤2). After format conversion, reads were mapped 
on genome by Project Wizzard Tool (Settings: Instrument 
type‑Illumina; Application type‑SNP/Indel discovery; 
Steps‑Sequence Alignment; Reference file‑Human_
GRCh_v37p10_dbsnp135; Allowable mismatched bases‑0; 
Allowable ambiguous alignments‑10; Seeds: 21 bases, move 
step‑1 base; Allowable alignments‑80; Overall matching base 
percentage ≥95%). Results of NextGENe software analysis 
(mutation report, expression report, coverage report, CNV 
analysis report) were filtered for the region of interest and 
mutation report additionally for the frequency of mutation 
allele >5%.
A variant comparison tool (NextGENe software; 
SoftGenetics, LLC) was used for the evaluation of 
shared/different mutations between the tumors of respective 
patients. Nonsynonymous variants in exons and adjacent 
intronic regions with frequency ≥10% in at least one tumor 
were evaluated and manually controlled using an IGV viewer 
(Broad Institute). Mutations detected with coverage under 
100x, which is caused by a limitation of the DNA quality from 
FFPE tissue, were manually controlled using an IGV viewer 
in both endometrial and ovarian tumors. These mutations are 
considered as true variants (not artefacts) if: i) The mutation 
was detected in both tumors of respective patient (in case of 
shared mutation); ii) reads with mutation excluded duplicates; 
and iii) variant was detected in both strands with different 
orientation of paired-end reads.
False calls of detected mutation in PIK3CA evaluated by 
NextGENe: p.(R524K), p.(Y644H), p.(E707K) were filtered 
out. The presence of a PIK3CA pseudogene on chromo-
some 22, with >95% sequence homology interferes with the 
detection of these variants (10).
The single nucleotide polymorphisms (SNPs; mutation 
allele frequency-MAF-above 0.01, i.e., above 1% in popula-
tion) were filtered out according to the data from the SNP 
databases (ExAC, 1,000 g, ESP6500) which are part of the 
mutation report generated by the NextGENe® Software. 
In order to assess the impact of the detected missense vari-
ants, several widely used in silico prediction programs or 
databases imported in NexteGENe Software were employed, 
comprising: ClinVar database, COSMIC database, and 
dbNSFP database (MetaSVM, MetaLR, RS_DBSNP141, SIFT, 
Polyphen2_HDIV, Polyphen2_HVAR, LRT, MutationTaster, 
MutationAssessor, FATHMM, PROVEAN GERP++, 
phyloP46, SiPhy). Clinical significance and ensemble predic-
tion scores were included in the NextGENe mutation reports.
Germline variants possibly associated with cancer predis-
posing syndromes were selected according to the following 
rules: i) VAF >40% in both tumors; ii) variants are not 
described as SNPs; and iii) clinical significance of the variant 
was assessed to be pathogenic and/or of uncertain signifi-
cance according to the ClinVar database. These variants were 
confirmed as germline mutations by Sanger sequencing of 
DNA isolated from non-tumor tissue.
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Analysis of microsatellite instability. Analysis of MSI was 
performed by fragmentation analysis on ABI 3500 (Thermo 
Fisher Scientific, Inc.) with the set of five quasimonomorphic 
mononucleotide microsatellite markers BAT-26, BAT-25, 
NR‑21, NR‑22 and NR‑24. The phenotype MSI‑high (MSI‑H) 
was defined as the presence of at least two instable loci and 
MSI-low as the presence of one instable locus, respectively. 
Microsatellite stable (MSS) tumors showed no instability.
Results
Clinico‑pathological findings. The characteristics of the 
patients and tumors are summarized in Fig. 1. From 22 cases, 
ten SEO cases were classified based on conventional 
morphological criteria as independent tumors, and twelve 
cases were considered as single primary tumors with metas-
tasis to the other location (ovary or endometrium). In three 
cases classified as metastasis from one location to the other 
peritoneal involvement was also found, and in one of these 
cases there was Fallopian tube involvement. A lymphadenec-
tomy procedure was performed in 11 patients, and only in one 
patient there was a metastasis found in one iliac lymph node.
The average age of diagnosis was 58 years (range, 
29-88 years). The average follow-up for all patients with 
available data (20 from 22 patients) was 37 months (range, 
1-122 months). Only 1 of the 10 (10%) patients (CS03) clas-
sified as independent SEO developed recurrent disease. This 
patient had a well-differentiated endometrioid carcinoma 
Figure 1. Spectrum of detected mutations. Tumor CS11 spreads to the peritoneum, CS18 spreads to the peritoneum, cervix and fallopian tube and CS22 
spreads to the peritoneum and cervix. Patient CS12 was diagnosed with colorectal carcinoma 15 months after primary EEC/EOC diagnosis, and patient CS15 
was diagnosed with EEC/EOC 41 months after a previous follicular lymphoma diagnosis. aClass according to the examination by pathologist using current 
criteria. Independent SEOs are tumors classified as independent synchronous endometrial and ovarian carcinoma. Metastatic SEOs are tumors classified as 
metastasis from one location to the other. bColored scale from red to green indicates the age of patients at diagnosis. CS, case specific; NED, no evidence 
of disease; RECUR, the recurrent disease was found during follow‑up; DOD, died of disease; NA, not available; MSS, microsatellite stable in EEC/EOC; 
MSI‑H, microsatellite instable in EEC/EOC; MSI‑H/MSS, case CS19 MSI‑H in EEC and MSS in EOC; EEC, endometrioid endometrial carcinoma; EOC, 
endometrioid ovarian carcinoma; FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; SEO, synchronous endometrial and ovarian carcinoma; 
MSI, microsatellite instability.
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of the left ovary treated by adnexectomy with subsequent 
pelvic and para-aortic lymphadenectomy, omentectomy and 
appendectomy. The SEO was found after 49 months in the 
form of a well-differentiated endometrioid carcinoma in the 
contralateral (right) ovary and in the endometrium, and it was 
treated by a combined radical hysterectomy and right adnex-
ectomy with subsequent chemotherapy [6 cycles of paclitaxel 
(PTX) and carboplatin (CBDCA)]. The patient is without any 
signs of disease 52 months after surgery. No patient from this 
group died of the disease. On the contrary, 2/12 patients with 
SEO classified as metastasis from one location to the other 
died of the disease. Another patient from this group developed 
metastatic disease 6 months after the diagnosis, the metastatic 
lesion was located in the abdominal wall and treated by a 
surgical excision. This patient was without any signs of the 
disease 11 months after the excision and then was lost to 
follow-up.
Molecular findings. The detected mutations are summarized 
in Fig. 1. Comparison of molecular profiles of independent and 
metastatic SEOs are shown in Fig. 2.
All of the SEOs (100%, 22/22) showed to be clonally 
related according to the presence of shared mutations (at 
least one). In 77.3% cases (17/22) a shared mutation in PTEN 
was detected and out of those, eight SEOs shared additional 
ARID1A mutation. Two SEOs (9%, 2/22) carried mutations in 
ARID1A, AKT1 and PIK3CA while PTEN was a wild-type. 
Another two cases carried only AKT1 mutation, which is a 
known pathogenic hot-spot p.(E17K) variant. Interestingly, 
one microsatellite instable SEO (CS15, both tumors of 
grade 2) shared pathogenic somatic mutation in HNF1B 
NM_000458.2: c.1561_1562insC, p.(Q521Pfs*30), both tumors 
carried mutations in MLH3, MLH1 and also further mutations 
in PTEN NM_000314.4: c.955_958del, p.(T319X), ARID1A 
NM_006015.4: c.5981delT, p.(V1994Gfs*21) and c.3667C>T, 
p.(R1223C), KRAS NM_004985.3: c.35G>A, p.(G12D) and 
TP53 NM_001126112.2: c.960_961del, p.(K321Tfs*15).
Two SEOs (CS02 and CS22) shared POLE mutation causing 
hypermutator phenotype (24 in EEC and 42 in EOC, 27 in 
EEC and 32 in EOC nonsynonymous mutations, respectively). 
As the evidence suggests, POLE hypermutator phenotype 
defines a unique subclass of endometrioid tumors. Moreover, 
in one patient (54-year-old patient-CS22) a germline PTEN 
mutation NM_000314.4: c.389G>A, rs121909229, p.(R130Q) 
was detected. Germline pathogenic PTEN mutations are 
usually associated with Cowden syndrome (PTEN hamartoma 
tumor syndrome). The association of the detected germline 
PTEN mutation with carcinogenesis in this particular patient 
is however questionable, due to the relatively high patient's age 
at the time of diagnosis and POLE hypermutator phenotype. In 
patient CS19, POLE mutation (29 nonsynonymous mutations 
detected in endometrial tumor), and microsatellite instability 
were detected in the endometrial tumor but not in the paired 
ovarian tumor, while both tumors shared the PTEN mutation.
Figure 2. Frequency of targeted gene mutations in metastatic and independent SEOs classified according to the current pathological criteria. SEO, synchronous 
endometrial and ovarian carcinoma.
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Fragment analysis showed microsatellite instable pheno-
type in 22.7% (5/22) of cases, including the above-mentioned 
case which was microsatellite instable only in the endometrial 
tumor.
Several germline mutations (germline status was confirmed 
by Sanger sequencing of DNA isolated from non-tumor tissue) 
in the genes which have been previously associated with 
cancer predisposing syndromes in the literature were detected. 
Two patients carried the pathogenic germline variant in 
BARD1 or BRCA1. The tumors of a 29-year-old patient (CS01) 
shared pathogenic nonsense germline mutation in BARD1 
NM_000465.2: c.1690C>T, rs587780021, p.(Q564X) together 
with shared somatic PTEN mutation. Another (32-year old 
patient-CS16) shared pathogenic frameshift germline muta-
tion in BRCA1 NM_007294.3: c.5266_5267insC, rs80357906, 
p.(Q1756Pfs*73) together with somatic TP53 mutation. Other 
germline mutations of uncertain clinical significance were 
detected in the genes BRCA1, BRCA2, MLH3 or MSH6.
In the case of CS06, a patient diagnosed with clear cell 
carcinoma of the ovary (CCCO) together with SEO, a different 
mutation profile was found in the respective tumors. The SEO 
shared common mutation in PTEN and KRAS, which was 
absent in CCCO, while the MSH6 mutation NM_000179.2: 
c.2873_2874del, p.(Q958Pfs*7) was detected only in CCCO.
Discussion
Synchronous endometrioid endometrial and ovarian carci-
nomas have been a matter of dispute especially because of the 
difficulties in differential diagnostics between two independent 
primary tumors and metastasis from one site to the other. The 
morphological criteria involved in their diagnostics comprise 
mainly the grade and stage of the diseases (3,4,8). In endome-
trial tumors the criteria include: Size of the tumor and depth of 
invasion, direct extension to the adnexa, lymphovascular space 
invasion, presence of atypical hyperplasia in the surrounding 
endometrium, and grading. In ovarian tumors the criteria 
include: The presence of endometriosis, size and laterality of 
the tumor, surface implants, hilar location, lymphovascular 
space invasion, and multinodularity. In general, several 
studies have confirmed that low stage (organ confined) and 
low-grade SEOs behave clinically as independent primary 
tumors. Moreover, it has been shown that women with stage I 
endometrioid endometrial cancer with synchronous stage I 
endometrioid ovarian cancer have a survival outcome similar 
to those patients with stage I endometrioid endometrial cancer 
without synchronous ovarian cancer (1,11-21). This is in 
concordance with the results of our study, as only 1/10 patients 
classified as independent SEO developed recurrent disease and 
none of these patients died of the disease.
Few studies have focused on which ancillary methods 
may be potentially helpful in the decision process, including 
immunohistochemical and molecular studies. The use of 
immunohistochemistry seems to be very limited and only few 
studies focused on assessing the expression of selected markers. 
One such study assessed the expression of cytokeratins, 
vimentin, CEA, Ca125 and Ca19.9 (22). The results between 
endometrial and ovarian tumors showed overlapping features 
and the authors concluded that in this setting, immunohisto-
chemistry is not beneficial. In another study, the authors used 
different antibodies including ER, PR, HER2, p53, and Ki‑67. 
They found out that some antibodies (ER, PR, bcl2) showed 
different immunostaining patterns between two primaries 
and can be used as a surrogate marker in the distinction of 
these tumors (23). Other study focused on vimentin expres-
sion in endometrial and ovarian endometrioid carcinoma (24). 
In this study the authors found that vimentin was negative in 
97% of primary ovarian carcinomas and positive in 82% of 
primary endometrial carcinomas. In SEOs the expression of 
vimentin was discordant in 53% of cases. They concluded that 
the expression of vimentin between endometrial and ovarian 
endometrioid carcinoma is different. However, the practical 
meaning of immunohistochemistry in this setting is disput-
able in light of the current knowledge that almost all EOC 
are clonal lesions and also, with respect to immunopheno-
typic tumor heterogeneity, can also be influenced by tumor 
microenvironment.
Molecular studies used variable approaches, including 
the assessing of microsatellite instability (MSI), the pattern 
of X chromosome inactivation, loss of heterozygosity (LOH), 
and mutation of single or small group of genes, especially 
PTEN and CTNNB1 (22,25-35). Most of the studies failed to 
identify the clonal origin in most of the cases analyzed. The 
results of these studies are disputable and limited, particu-
larly with regards to the used methodology. Analysis of a 
limited number of markers did not allow a comprehensive 
evaluation and comparison of possible clonal origin of all 
tumors. In view of current knowledge, it is clear that the 
intratumoral and intermetastatic heterogeneity is relatively 
common and can be influenced by several factors such as 
tumor type, presence of driver mutations, mutation load, and 
also by immune host reaction with clonal selection. Only 
three recent studies focused on the comparison between 
endometrial and ovarian tumors by NGS approach (5-7). One 
of these studies analyzed 18 SEO cases (all but two were 
endometrioid in type; the two exceptions were ovarian clear 
cell carcinoma and endometrial endometrioid carcinoma), 
11 of them were classified based on conventional criteria 
as independent primary tumors. The authors used targeted 
sequencing of 35 genes commonly altered in endometrial and 
ovarian tumors. Their results showed that 17/18 cases were 
of clonal origin, including 10/11 cases based on conventional 
criteria classified as independent tumors (6). The second 
study analyzed 23 SEOs, with 15 of being classified as inde-
pendent primary tumors. Five of these cases were analyzed 
by whole-exome sequencing, the remaining 18 cases were 
analyzed by NGS targeting of 341 (n=4) or 410 (n=14) genes, 
respectively. Their results showed that all sporadic SEOs 
were clonally related. The only exception was a SEO in 
patient with Lynch syndrome with germline MSH6 mutation 
in which the somatic mutations were different. The last study 
analyzed 14 cases by NGS targeting of 409 genes and by 
genome-wide copy number analysis by MIP microarrays (7). 
Thirteen of their cases showed evidence of clonality. In our 
present study we found that all 22 synchronous EECs and 
EOCs shared nonsynonymous mutations in at least one gene: 
PTEN, AKT1, PIK3CA, KRAS, TP53 and ARID1A. These 
findings suggest that the relatively small panel of genes 
included in the NGS analysis can be a very useful approach 
to confirming clonal relation of SEOs.
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The results of all these 3 molecular studies were very 
similar and are in concordance with the results of our study, 
the most important findings being: i) almost all SEOs are of 
clonal origin and even low stage and low-grade tumors seem 
to represent dissemination from one site to the other (however, 
without a possibility to conclusively assess the directionality); 
ii) all sporadic SEOs shared nonsynonymous mutations in at 
least one cancer driver gene of EEC and/or EOC. The authors 
suggest that the low grade and low stage SEOs, despite being 
clonal in origin, probably represent phenomenon of restricted 
dissemination colonizing only certain types of microenviron-
ments and represent clinically indolent spread and not a sign of 
a ‘fully’ metastatic disease. A possible explanation is that SEOs 
classified as independent tumors, using conventional criteria, 
represent mostly primary indolent endometrial tumors with 
spread through the Fallopian tube and seeding of the implant 
into the ovary. This explanation is supported by the finding that 
SEO tumors showed a lower frequency of ovarian endometriosis 
than sporadic ovarian endometrioid carcinomas (36).
Based on the results of our study and other three recent 
studies focusing on this topic the benefit of molecular analysis 
used for differential diagnosis between independent primary 
tumors and metastatic disease is disputable (5-7). The finding 
of clonal origin of almost all SEOs is very important and 
contrary to the belief that molecular testing could be used as 
a tool for differential diagnosis. Still, this issue has not been 
solved and in one recent study the authors suggest that molec-
ular profiling may be beneficial in this setting (8). However, 
this suggestion was based on whole exome sequencing of only 
one case of SEO. In their case the authors detected 253 shared 
mutations (including ARID1A, PIK3CA, MSH6 and intronic 
mutation in PTEN), but more mutations were found only in 
EEC or EOC. Despite the findings of shared mutations, they 
proposed that these tumors were clonally unrelated and classi-
fied them as synchronous independent tumors.
Regardless of the significance in assessing the clonality 
of an SEO, our results showed some interesting findings with 
respect to the spectrum of molecular changes occurring in the 
analyzed tumors. Pathogenic germline mutations in BARD1 or 
BRCA1, which are usually associated with cancer predisposing 
syndromes, were detected in two patients with SEOs. Germline 
BARD1 mutation p.(Q564X) has been previously described in 
families with members affected by breast, colon and uterine 
cancer (37). Germline BRCA1 mutation p.(Q1756Pfs*73) is 
a known founder mutation in the Ashkenazi Jewish popula-
tion and in several European countries including the Czech 
Republic (38,39). This finding is important for proper genetic 
counseling besides Lynch syndrome, the common predis-
posing syndrome associated with uterine tumors.
Pathogenic somatic HNF1B mutation NM_000458.2: 
c.1561_1562insC, p.(Q521Pfs*30) shared in the SEO of one 
patient (CS15) represents the insertion of one nucleotide 
(cysteine affecting codon 521 located in exon 8 polyC (C)7 
sequence) resulting in frameshift and protein truncation. This 
mutation in the polyC segment might possibly be the result 
of the microsatellite instability of these tumors (mutated 
MLH3 and MLH1). The tumors carried further pathogenic 
or likely pathogenic somatic mutations in PTEN, ARID1A, 
KRAS, and TP53. Nevertheless, the HNF1B p.(Q521Pfs*30) 
mutation has been previously described in two stomach 
adenocarcinomas (40) and in four renal clear cell carcinomas 
according to the TCGA atlas (study Kidney Renal Clear Cell 
Carcinoma) (41). All those tumors carried also at least one of 
the mutations in ARID1A, TP53 (frameshift variant), PTEN 
and/or KRAS, which suggests a similar mutation profile in 
different types of tumors. The incidence and significance 
of HNF1B mutations in EEC is unknown. However, in our 
previous study we detected another pathogenic truncation 
mutation of this gene c.454C>T, p.( Q152X) in 1/30 EEC (42).
In conclusion, based on our results and the results of three 
previously published comprehensive molecular studies of 
SEOs, these tumors are clonally related in almost all cases 
irrespectively of their clinico-pathological features. Even low 
grade and low stage tumors classified as independent prima-
ries, according to the conventional morphological criteria, 
have a clonal origin. From the practical point of view, only 
the conventional morphological criteria should be used for 
the classification of these tumors, while molecular profiling 
does not seem, in this context, helpful. However, analysis of 
more cases is needed to draw a definite conclusion. Despite 
this fact, the molecular studies of SEOs can help us to better 
understand the pathogenesis of SEOs and can be beneficial in 
clinical practice for example in cases of metachronous tumors 
affecting female genital organs and/or peritoneum, or in cases 
of metastatic tumors (43,44). Moreover, molecular profiling of 
SEOs can be also significant with respect to prognostic and 
also predictive meaning.
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